Skip to main content
    R

    Roivant Sciences Ltd (ROIV)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $38.61
    -0.92 (-2.33%)

    Market Cap: $28.64B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Roivant Sciences Ltd (ROIV) Financials: Revenue, Profit and Cash Flow

    Updated Nov 9, 2026. Financial statements from company filings, amounts in US dollars.

    Roivant Sciences reported revenue of $8.26M for the fiscal year ended Mar 31, 2026, down 71.6% from the year before. That year, net income was -$397.91M with a net margin of -4817.3%, operating cash flow was -$750.35M and free cash flow was -$758.56M. The quarter ended Sep 30, 2026 had revenue of $35.12M and net income of -$137.21M.

    Revenue and Margins

    Over the 7 years to Mar 2026, revenue grew from $2.32M, a compound annual rate of 19.9%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Mar 2026$8.26M-71.6%100.0%-6235.7%-4817.3%
    Mar 2025$29.05M-11.2%100.0%-3453.3%-1227.9%
    Mar 2024$32.71M+3.8%100.0%13746.9%12934.3%
    Mar 2023$31.53M-43.0%100.0%-2875.9%-3537.8%
    Mar 2022$55.29M+132.3%100.0%-2444.8%-1671.5%
    Mar 2021$23.80M-64.8%100.0%-4500.5%-3783.3%
    Mar 2020$67.69M+2812.6%98.3%-786.6%1773.6%
    Mar 2019$2.32MN/A73.9%-32207.0%-44835.2%
    Annual, fiscal years ended Mar 2019 to Mar 2026

    Income Statement

    In the fiscal year ended Mar 2026, the net loss widened from the year before. In the quarter ended Sep 2026, the net loss narrowed from the same quarter a year earlier.

    Annual

    Line itemMar 2026Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020Mar 2019
    Revenue$8.26M$29.05M$32.71M$31.53M$55.29M$23.80M$67.69M$2.32M
    Cost of revenue$0$0$0$0$0$0$1.13M$606.00K
    Gross profit$8.26M$29.05M$32.71M$31.53M$55.29M$23.80M$66.56M$1.72M
    Research and development$681.81M$550.41M$466.36M$551.81M$622.93M$832.76M$263.22M$512.99M
    Operating income-$515.07M-$1.00B$4.50B-$906.76M-$1.35B-$1.07B-$532.42M-$748.49M
    Net income-$397.91M-$356.73M$4.23B-$1.12B-$924.12M-$900.23M$1.20B-$1.04B
    EBITDAN/AN/AN/AN/A-$1.27BN/AN/A$138.13M
    Fiscal years ended Mar 2019 to Mar 2026

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$35.12M$1.44M$2.52M$2.00M$1.57M$2.17M$7.57M$9.02M$4.47M$7.99M-$8.12M$15.56M
    Gross profit$31.77M$1.44M$2.67M$2.00M$1.46M$2.17M$7.78M$9.02M$4.47M$7.78M-$8.12M$15.56M
    Operating income-$268.05M-$365.99M$415.24M-$339.15M-$306.23M-$284.92M-$284.96M-$274.38M-$341.71M-$102.23M-$140.12M$5.13B
    Net income-$137.21M-$290.61M$355.74M-$313.70M-$166.04M-$273.91M-$252.38M$118.08M-$279.92M$57.49M-$182.50M$5.07B
    Last 12 quarters

    Balance Sheet

    As of Mar 2026, cash and equivalents exceeded short-term debt of $11.15M by $1.41B.

    Annual

    Line itemMar 2026Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020Mar 2019
    Total assets$5.71B$5.44B$7.22B$2.39B$2.59B$2.59B$2.48B$1.39B
    Current assets$5.17B$5.00B$6.73B$1.80B$2.15B$2.19B$2.22B$1.19B
    Cash and equivalents$1.42B$2.72B$6.49B$1.68B$2.06B$2.06B$2.19B$849.55M
    Total liabilities$416.27M$249.74M$773.95M$782.02M$523.70M$527.69M$368.36M$450.51M
    Short-term debt$11.15M$9.84M$21.89M$40.72M$0$12.31M$7.84M$21.18M
    Long-term debtN/AN/A$430.59M$375.51M$210.03M$170.28MN/AN/A
    Shareholder equity$4.53B$4.69B$5.97B$1.16B$1.66B$1.80B$2.03B$937.30M
    Fiscal years ended Mar 2019 to Mar 2026

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$4.98B$5.31B$5.73B$5.23B$5.06B$5.03B$5.44B$5.79B$6.21B$6.50B$7.22B$7.31B
    Total liabilities$380.10M$384.62M$435.63M$251.14M$257.14M$216.70M$249.74M$256.38M$625.99M$601.16M$773.95M$728.10M
    Cash and equivalents$1.64B$1.25B$1.42B$1.48B$1.24B$1.24B$2.72B$1.99B$1.96B$5.68B$6.54B$6.67B
    Shareholder equity$4.02B$4.23B$4.53B$4.27B$4.36B$4.35B$4.69B$5.19B$5.15B$5.44B$5.97B$6.09B
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Mar 2026.

    Annual

    Line itemMar 2026Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020Mar 2019
    Operating cash flow-$750.35M-$839.45M-$765.27M-$843.39M-$677.73M-$552.14M-$761.83M-$1.02B
    Capital expenditures$8.21M$4.60M$1.38M$12.69M$17.44M$5.81M$4.92M$11.40M
    Free cash flow-$758.56M-$844.05M-$766.65M-$856.08M-$695.16M-$557.94M-$766.75M-$1.04B
    Dividends paid$0$0$6.00M$0N/AN/AN/AN/A
    Share repurchases$319.50M$1.29B$0$0N/AN/AN/AN/A
    Investing cash flow-$682.33M-$1.77B$5.20B-$44.27M$303.30M-$31.70M$1.69B-$57.61M
    Financing cash flow$134.24M-$1.22B$419.36M$499.46M$306.79M$456.26M$217.16M$767.02M
    Fiscal years ended Mar 2019 to Mar 2026

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow$594.42M-$270.50M-$163.82M-$196.48M-$185.66M-$204.38M-$172.56M-$207.25M-$266.81M-$192.83M-$108.46M-$210.45M
    Capital expenditures$208.00K$419.00K$1.26M$4.93M$7.85M$4.04M$811.00K$1.83M$996.00K$965.00K$349.00K$355.00K
    Free cash flow$594.21M-$270.92M-$165.08M-$201.42M-$193.51M-$208.42M-$173.38M-$209.08M-$267.80M-$193.79M-$108.81M-$210.81M
    Last 12 quarters

    Frequently Asked Questions About ROIV

    What is Roivant Sciences' annual revenue?

    Roivant Sciences reported revenue of $8.26M for the fiscal year ended Mar 31, 2026.

    How fast is Roivant Sciences' revenue growing?

    Revenue was down 71.6% for the fiscal year ended Mar 31, 2026 compared with the year before. The compound annual revenue growth rate over 3 years was -36.0%.

    Is Roivant Sciences profitable?

    No. Roivant Sciences reported net income of -$397.91M for the fiscal year ended Mar 31, 2026, with a net margin of -4817.3%.

    How much free cash flow does ROIV generate?

    For the fiscal year ended Mar 31, 2026, operating cash flow of -$750.35M minus capital expenditures of $8.21M produced free cash flow of -$758.56M.

    How much debt does Roivant Sciences have?

    The balance sheet dated Mar 31, 2026 reported short-term debt of $11.15M and cash and equivalents of $1.42B.